Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point

Research output: Contribution to journalArticle

  • Authors:
  • Emma C Y Hilton
  • Paul G. Baverel
  • Ashley Woodcock
  • Piet H. Van Der Graaf
  • Jaclyn A. Smith


Background: Inhaled capsaicin elicits cough reproducibly in human subjects and is widely used in the study of cough and antitussive therapies. However, the traditional end points C2 and C5 (the concentrations of capsaicin inducing at least 2 or 5 coughs, respectively) display extensive overlap between health and disease and therefore might not best reflect clinically relevant mechanisms. Objectives: We sought to investigate capsaicin dose responses in different disease groups. Methods: Two novel capsaicin cough challenges were compared in patients with chronic cough (CC; n = 20), asthmatic patients (n = 18), and healthy volunteers (HVs; n = 20). Increasing doubling doses of capsaicin (0.48-1000 μmol/L, 4 inhalations per dose) were administered in challenge 1, whereas the order of the doses was randomized in challenge 2. A nonlinear mixed-effects model compared dose-response parameters by disease group and sex. Parameters were also correlated with objective cough frequency. Results: The model classified subjects based on maximum cough response evoked by any concentration of capsaicin (Emax) and the capsaicin dose inducing half-maximal response (ED50). HVs and asthmatic patients were not statistically different for either parameter and therefore combined for analysis (mean ED50, 38.6 μmol/L [relative SE, 28%]; mean Emax, 4.5 coughs [relative SE, 11%]). Compared with HVs/asthmatic patients, patients with CC had lower ED50 values (14.7 μmol/L [relative SE, 28%], P =.008) and higher Emax values (8.6 coughs [relative SE, 11%], P

Bibliographical metadata

Original languageEnglish
Pages (from-to)847-e5
JournalJournal of Allergy and Clinical Immunology
Issue number4
Publication statusPublished - Oct 2013